English
-
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
06/20/2024 - 07:30 PM
-
Bunge Announces Sale of its Ownership Share in its Sugar and Bioenergy Joint Venture in Brazil
06/20/2024 - 07:30 PM
-
06/20/2024 - 07:28 PM
-
Dexcom Expands AID Partnership Into The Netherlands
06/20/2024 - 07:15 PM
-
FitVine Launches New Aluminum Wine Bottles Designed for Active, Wellness Minded Consumers
06/20/2024 - 07:09 PM
-
EVgo Names Keith Hutchison as Company’s First Chief People Officer
06/20/2024 - 07:00 PM
-
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
06/20/2024 - 07:00 PM
-
F9 to LL Flooring Board: Stop the Charade! LL Flooring’s Letter and Presentation Are Filled With Distortions of the Facts and Dishonest Personal Attacks
06/20/2024 - 07:00 PM
-
Westlake Epoxy Receives EcoVadis Gold Rating
06/20/2024 - 07:00 PM
-
Groundbreaking Exosome Skincare Brand ( plated )™ Launches First-of-Its-Kind Hair Serum Powered by Award-Winning Renewosome™ Technology
06/20/2024 - 07:00 PM
-
ConnexPay Adds Kurt Adams to Board of Directors
06/20/2024 - 07:00 PM
-
K2 International Launches K2 Rubicon Specialty
06/20/2024 - 07:00 PM
-
Laser Photonics & Echelon 1 Solutions Team Up To Deliver Laser Power to Defense Agencies
06/20/2024 - 07:00 PM
-
Yukon Supports Tenex Capital Management’s Investment in Behavioral Innovations
06/20/2024 - 07:00 PM
-
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/20/2024 - 07:00 PM